Who
John Johnson
Director
Company insider
Files Form 4 as: Director, Axogen; Director, Xeris Biopharma Holdings; Director, Verastem; Executive Chairman, Applied Therapeutics; Chief Executive Officer, Strongbridge Biopharma; Director, Portola Pharmaceuticals; Chief Executive Officer, Melinta Therapeutics, Inc. /new/; Director, Ocugen.
In numbers
- Trades disclosed
- 187
- Buys
- 7
- Sells
- 9
- Bought
- $759K
- Sold
- $4.4M
- Companies
- 14
- Companies where not an officer
- 8
- First trade
- 27 Aug 2007
- Last trade
- 24 Jun 2026
- Last filed
- 26 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 24 Jun 2026filed 26 Jun 2026 | AXGN Axogenoption or derivative · Medical Devices | SEC FORM 4 Code A | —4,392 at $0.00 | filing |
| 24 Jun 2026filed 26 Jun 2026 | AXGN Axogenoption or derivative · Medical Devices | SEC FORM 4 Code A | —4,392 at $0.00 | filing |
| 19 Jun 2026filed 23 Jun 2026 | AXGN AxogenMedical Devices | SEC FORM 4 Code M | —14,150 at $0.00 | filing |
| 19 Jun 2026filed 23 Jun 2026 | AXGN Axogenoption or derivative · Medical Devices | SEC FORM 4 Code M | —14,150 at $0.00 | filing |
| 19 Jun 2026filed 23 Jun 2026 | AXGN Axogenoption or derivative · Medical Devices | SEC FORM 4 Code M | —14,150 at $0.00 | filing |
| 19 Jun 2026filed 23 Jun 2026 | AXGN AxogenMedical Devices | SEC FORM 4 Code M | —14,150 at $0.00 | filing |
| 4 Jun 2026filed 5 Jun 2026 | XERS Xeris Biopharma HoldingsBiotechnology | SEC FORM 4 Sold | $91K15,000 at $6.09 | filing |
| 4 Jun 2026filed 5 Jun 2026 | XERS Xeris Biopharma HoldingsBiotechnology | SEC FORM 4 Code A | —24,193 at $0.00 | filing |
| 4 Jun 2026filed 5 Jun 2026 | XERS Xeris Biopharma Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code A | $203K32,996 at $6.15 | filing |
| 4 Jun 2026filed 5 Jun 2026 | XERS Xeris Biopharma Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code A | $203K32,996 at $6.15 | filing |
| 4 Jun 2026filed 5 Jun 2026 | XERS Xeris Biopharma HoldingsBiotechnology | SEC FORM 4 Sold | $91K15,000 at $6.09 | filing |
| 4 Jun 2026filed 5 Jun 2026 | XERS Xeris Biopharma HoldingsBiotechnology | SEC FORM 4 Code A | —24,193 at $0.00 | filing |
| 21 May 2026filed 26 May 2026 | VSTM VerastemBiotechnology | SEC FORM 4 Code A | —36,000 at $0.00 | filing |
| 21 May 2026filed 26 May 2026 | VSTM VerastemBiotechnology | SEC FORM 4 Code A | —36,000 at $0.00 | filing |
| 7 May 2026filed 8 May 2026 | AXGN AxogenMedical Devices | SEC FORM 4 Code M | $78K11,050 at $7.04 | filing |
| 7 May 2026filed 8 May 2026 | AXGN AxogenMedical Devices | SEC FORM 4 Sold | $478K11,050 at $43.26 | filing |
| 7 May 2026filed 8 May 2026 | AXGN Axogenoption or derivative · Medical Devices | SEC FORM 4 Code M | —11,050 at $0.00 | filing |
| 7 May 2026filed 8 May 2026 | AXGN Axogenoption or derivative · Medical Devices | SEC FORM 4 Code M | —11,050 at $0.00 | filing |
| 7 May 2026filed 8 May 2026 | AXGN AxogenMedical Devices | SEC FORM 4 Code M | $78K11,050 at $7.04 | filing |
| 7 May 2026filed 8 May 2026 | AXGN AxogenMedical Devices | SEC FORM 4 Sold | $478K11,050 at $43.26 | filing |
News
Reviewing MediciNova (NASDAQ:MNOV) & Xeris Biopharma (NASDAQ:XERS)XERS · dailypolitical.com · 22 Oct 2026Critical Contrast: Organon & Co. (NYSE:OGN) & Xeris Biopharma (NASDAQ:XERS)XERS · tickerreport.com · 21 Oct 2026Analyzing GE HealthCare Technologies (NASDAQ:GEHC) & AxoGen (NASDAQ:AXGN)AXGN · tickerreport.com · 21 Oct 2026Head-To-Head Survey: Organon & Co. (NYSE:OGN) versus Xeris Biopharma (NASDAQ:XERS)XERS · themarketsdaily.com · 19 Oct 2026Analyzing AxoGen (NASDAQ:AXGN) & AtriCure (NASDAQ:ATRC)AXGN · tickerreport.com · 18 Oct 2026
0 headlines in the last 90 days name John Johnson; 5 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.